Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY 11.07.2024

Full Press ReleaseSEC FilingsOur INCY Tweets

About Gravity Analytica

Recent News

  • 02.10.2025 - Q4 2024 Incyte Corporation Earnings Conference Call
  • 01.21.2025 - Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
  • 01.15.2025 - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.21.2025 - 144 Report of proposed sale of securities
PDF Version

WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 7, 2024--Incyte(Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an aggregate of 15,812 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date ofNovember 1, 2024, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU vests as to 25% of the shares subject to the RSU on each of the first four anniversaries of the vesting commencement date, subject to the employee's continued service with the Company on each such date. The stock options have an exercise price of$76.13per share, which is equal to the closing price of the Company’s common stock on the grant date. Each stock option has a ten-year term and vests as to 25% of the original number of shares subject to the stock option on the one-year anniversary of the vesting commencement date with the remainder vesting in 36 successive equal monthly installments, subject to the employee’s continued service with the Company on each such date.

AboutIncyte

A global biopharmaceutical company on a mission toSolve On.,Incytefollows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics,Incytehas established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered inWilmington, Delaware,Incytehas operations inNorth America,EuropeandAsia.

For additional information onIncyte, please visitIncyte.comor follow us on social media:LinkedIn,X,Instagram,Facebook,YouTube.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107350573/en/

Mediamedia@incyte.com

Investorsir@incyte.com

Source:Incyte

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com